



**California State Board of Pharmacy**  
2720 Gateway Oaks Drive, Ste 100  
Sacramento, CA 95833  
Phone: (916) 518-3100 Fax: (916) 574-8618  
www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency  
Department of Consumer Affairs  
Gavin Newsom, Governor



**To: Board Members**

**Subject: VIII. Discussion and Possible Action to Rescind Prior Board Motion to Initiate a Rulemaking to add Sections 1750 and 1750.1 to Title 16 of the California Code of Regulations Related to Outsourcing Facilities.**

---

**Relevant Law**

[Business and Professions Code sections 4129 – 4129.9](#) generally establish the licensure and operational requirements for Outsourcing Facilities.

**Background:**

At its October 2022 meeting, the Board voted to initiate a rulemaking to add sections 1750 and 1750.1 to title 16 of the California Code of Regulations to address changes in pharmacy law regarding outsourcing facilities and their authority to dispense patient-specific compounded preparations based on prescriptions. Specifically, this rulemaking would establish a self-assessment process for these outsourcing facilities. A copy of the draft regulatory text and self-assessment form are included at **Attachment 1**.

Board staff drafted initial rulemaking documents and submitted them to the Department for pre-notice review on February 6, 2023. The documents were resubmitted to Board staff for edits on May 16, 2024, and approved by the Department on October 2, 2024.

The Board's sunset bill, Assembly Bill (AB) 1503 (Berman, Chapter 196, Statutes of 2025), extends the Board's operations through January 1, 2030. The bill also addresses several policy issues identified in the Board's 2025 Sunset Oversight Review Report. Signed by Governor Newsom on October 1, 2025, AB 1503 places the self-assessment process into statute, making the previously proposed regulation unnecessary.

**At this Meeting:**

During the meeting, members will have an opportunity to discuss and determine if the motion to initiate this rulemaking should be rescinded. Should members agree, provided below is possible motion language.

**Possible Motion:**

Rescind the October 26, 2022, motion to initiate a rulemaking to add sections 1750 and 1750.1 to title 16 of the California Code of Regulations.

# **Attachment 1**

## Title 16. Board of Pharmacy

### Proposal To Add Article 6.5 and Sections 1750 and 1750.1 in Division 17 of Title 16 of the California Code of Regulations to read as follows:

#### Article 6.5 Outsourcing Facilities

##### 1750 Outsourcing Facility Requirements

- (a) Each outsourcing facility defined under section 4034 of the Business and Professions Code shall compound all sterile products and nonsterile products in compliance with federal current good manufacturing practices (cGMP) applicable to outsourcing facilities under section 501 (a) (2) (B) of the Federal Food, Drug, and Cosmetic Act (21 USC § 351 (a) (2) (B)) and shall meet the requirements of this Article.
- (b) In addition to subsections (a) and (c), an outsourcing facility licensed pursuant to Business and Professions Code sections 4129.1 or 4129.2 shall comply with all applicable federal and state laws and regulations, including all of the following:
  - (1) Code of Federal Regulations, Title 16, Chapter II, Subchapter E, Part 1700 (commencing with section 1700.1) – Poison Prevention Packaging,
  - (2) Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 210 (commencing with section 210.1) – Current Good Manufacturing Practice in Manufacturing, Processing, Packaging, or Holding of Drugs; General,
  - (3) Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 211 (commencing with section 211.1) – Current Good Manufacturing Practice for Finished Pharmaceuticals,
  - (4) Code of Federal Regulations, Title 21, Chapter II, Parts 1301 (commencing with section 1301.01) – Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances,
  - (5) Code of Federal Regulations, Title 21, Chapter II, Part 1304 (commencing with section 1304.01) – Records and Reports of Registrants with the Drug Enforcement Administration,
  - (6) Code of Federal Regulations, Title 21, Chapter II, Part 1305 (commencing with section 1305.01) -- Orders for Schedule I and II Controlled Substances,
  - (7) Code of Federal Regulations, Title 21, Chapter II, Part 1306 (commencing with section 1306.01) -- Prescriptions,
  - (8) Code of Federal Regulations, Title 21, Chapter II, Part 1311 (commencing with section 1311.01 -- Requirements for Electronic Orders and Prescriptions,

- (9) The Uniform Controlled Substances Act (Health and Safety Code, Division 10 (commencing with section 11000)),
  - (10) Chapters 1, 4, 6 and 8 of the Sherman Food, Drug, and Cosmetics Law (Health and Safety Code, Division 104, Part 5 (commencing with Section 109875) -,
  - (11) United States Code, Title 21, Chapter 9, Subchapter V, Part A (commencing with section 351) – Drugs and Devices, and,
  - (12) United States Code, Title 21, Chapter 13, Part C (commencing with section 821) – Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances, except for sections 821, 822a, and 826a of that Part.
- (c) An outsourcing facility licensed pursuant to Business and Professions Code sections 4129.1 or 4129.2 shall dispense patient-specific compounded preparations pursuant to a prescription for an individual patient in compliance with all applicable provisions of state and federal laws and regulations relating to a pharmacy as follows:
- (1) Orally transmitted prescriptions are received and reduced to writing by a pharmacist consistent with the provisions of Business and Professions Code section 4070 and section 1717(c) of this Division and are issued by an appropriately licensed prescriber.
  - (2) Internet prescriptions are only dispensed pursuant to a prior good faith examination as required in Business and Professions Code section 4067(a) and are issued only by an appropriately licensed prescriber.
  - (3) Electronic prescriptions meeting the requirements of Business and Professions Code section 688 are issued only by an appropriately licensed prescriber.
  - (4) Controlled substances prescriptions meet the requirements of Health and Safety Code sections 11164(a), 11164.5, 11167.5, and 11162.1 and Business and Professions Code section 688.
  - (5) Each prescription contains all information required by Business and Professions Code sections 4040 and 4070.
  - (6) Each prescription label complies with the provisions of Business and Professions Code sections 4076, 4076.5, and 4076.6 and section 1707.5 of this Division.
  - (7) Drug warnings are provided orally or in writing consistent with the provisions of Business and Professions Code sections 4074 and 4076.7, section 1744 of this Division, and section 290.5 of Title 21 of the Code of Federal Regulations.

- (8) Prescriptions are dispensed in containers meeting the requirements of section 1473(b) of Title 15 of the United States Code, section 1700.15 of Title 16 of the Code of Federal Regulations, and section 1717(a) of this Division.
  - (9) Patient consultation is provided consistent with the provisions of section 1707.2 of this Division.
  - (10) Prior to consultation as required in section 1707.2, a pharmacist shall review drug therapy and patient medication records consistent with the provisions of section 1707.3 of this Division.
  - (11) The facility shall maintain medication profiles consistent with the provisions of section 1707.1 of this Division.
  - (12) All Schedule II through V controlled substance dispensing data are reported to the CURES Prescription Drug Monitoring Program as required in Health and Safety Code section 11165.
  - (13) A pharmacist communicates with the patient or patient's agent if a medication error occurs consistent with the provisions of section 1711.
  - (14) Medication errors must be documented as part of the facility's quality assurance program consistent with the provisions of Business and Professions Code section 4125 and section 1711 of this Division.
  - (15) Patient information and prescriptions are kept confidential consistent with the provisions of the Confidentiality of Medical Information Act (Civil Code sections 56 and following), and section 1764 of this Division.
  - (16) Prescription refills must comply with Business and Professions Code section 4063, Health and Safety Code section 11200, and sections 1717 and 1717.5 of this Division.
  - (17) All records of disposition are maintained for at least three years consistent with Business and Professions Code sections 4081 and 4105.
- (d) For the purposes of this section, "appropriately licensed prescriber" shall mean any health care professional listed in Section 4040(a)(2) of the Business and Professions Code.

**Proposal to Add Section 1750.1 to Article 6.5 of Division 17 of Title 16 of the California Code of Regulations to read as follows:**

**1750.1 Self-Assessment of an Outsourcing Facility (Resident and Nonresident)**

- (a) Each outsourcing facility as defined under section 4034 of the Business and Professions Code shall complete a self-assessment of its compliance with federal and state pharmacy law. The assessment shall be performed by the outsourcing facility's designated quality control personnel, before July 1 of

every odd-numbered year. The primary purpose of the self-assessment is to promote compliance through self-examination and education, for compliance with federal current good manufacturing practices as referenced in section 1750 (cGMP) and provisions of state law related to pharmacies, Pharmacy law and this Division related to patient specific prescriptions. For the purposes of this section, “designated quality control personnel” shall mean an individual or individuals from the quality control unit as defined in section 211.22 of Title 21 of the Code of Federal Regulations (“quality control unit”) identified by the outsourcing facility as the person or persons responsible for the facility’s operations as detailed in the FDA Current Good Manufacturing Practice – Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act, Guidance for Industry.

- (b) Each outsourcing facility shall designate a member of the quality control unit to be responsible for compliance with this section. The name and job title of the designated member must be maintained as part of the records of the outsourcing facility in accordance with Business and Professions Code section 4081.
- (c) In addition to the self-assessment required in subdivision (a) of this section, the designated quality control personnel shall complete a self-assessment within 30 days whenever:
  - (1) A new outsourcing facility license is issued.
  - (2) There is a change in the designated quality control personnel.
  - (3) There is a change in the licensed physical location of an outsourcing facility to a new address.
- (d) Each outsourcing facility licensed pursuant to Business and Professions Code sections 4129.1 or 4129.2 shall complete the “Outsourcing Facility Self-Assessment,” Form 17M-117 (New. 9/2022), which is hereby incorporated by reference and contains the following components:
  - (1) The designated quality control personnel shall provide identifying information about the outsourcing facility including:
    - (A) Name, license number of the premises, and the license expiration date;
    - (B) Address, phone number, website address, if applicable, and type of ownership;
    - (C) U.S. Food and Drug Administration (FDA) Federal Establishment Identification number, expiration date and date of most recent

- inspection completed by the FDA pursuant to Section 360 of Title 21 of the United States Code;
- (D) Federal Drug Enforcement Administration (DEA) registration number and expiration date and date of most recent DEA inventory pursuant to Title 21, Code of Federal Regulations section 1304.11; and,
  - (E) Hours of operation of the licensee.
- (2) The designated quality control personnel shall list the name of each staff person involved in the dispensing of patient specific prescriptions at the facility at the time the self-assessment is completed, and each person's role within the facility's operations.
  - (3) The designated quality control personnel shall respond "yes", "no" or "not applicable" (N/A) about whether the licensed premises is, at the time of the self-assessment, in compliance with each of the requirements.
  - (4) For each "no" response, the designated quality control personnel shall provide a written corrective action or action plan describing the actions to be taken to come into compliance with the applicable law or regulation cited on the self-assessment form for which a "no" response was provided.
  - (5) The designated quality control personnel shall initial each page of the self-assessment form with original handwritten initials in ink or digitally signed in compliance with Civil Code section 1633.2(h) on the self-assessment form.
  - (6) The designated quality control personnel shall certify, under penalty of perjury of the laws of the State of California, on the final page of the self-assessment that:
    - (A) They have completed the self-assessment of the licensed premises for which they are responsible;
    - (B) Any deficiency identified within the self-assessment will be corrected and list the timeframe for correction;
    - (C) They acknowledge receiving the following notice: "All responses on this form are subject to verification by the Board of Pharmacy"; and,
    - (D) The information provided in the self-assessment form is true and correct.
    - (E) The certification, made under penalty of perjury of the laws of the State of California that the information provided in the self-

assessment form is true and correct, may be an original handwritten signature in ink or digitally signed in compliance with Civil Code section 1633.2(h) on the self-assessment form.

- (7) The licensed premises owner, partner or corporate officer shall certify on the final page of the self-assessment that they have read and reviewed the completed self-assessment and have received notice that failure to correct any deficiency identified in the self-assessment could result in the revocation of the license issued by the board. The certification shall be made, under penalty of perjury of the laws of the State of California, that the information provided in the self-assessment form is true and correct with an original handwritten signature in ink or digitally signed in compliance with Civil Code section 1633.2(h) on the self-assessment form.
- (e) Each self-assessment shall be completed in its entirety and kept on file in the licensed premises for three years after it is completed. The completed, initialed, and signed original must be readily available for review during any inspection in accordance with Business and Professions Code section 4081.
- (f) The outsourcing facility is responsible for compliance with this article.
- (g) Any identified areas of deficiency identified in the self-assessment shall be corrected as specified in the timeframe listed in the certification as provided in subsection (d)(6).

Note: Authority cited: Section 4005, Business and Professions Code. Reference: Sections 4034, 4129- 4129.9, Business and Professions Code.



**California State Board of Pharmacy**  
 2720 Gateway Oaks Drive, Ste. 100  
 Sacramento, CA 95833  
 Phone: (916) 518-3100 Fax: (916) 574-8618  
 www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency  
 Department of Consumer Affairs  
 Gavin Newsom, Governor



### **Outsourcing Facility Self-Assessment**

Sections 4129.1(b) and 4129.2(b) of the Business and Professions Code (BPC) and section 1750 of Title 16 of the California Code of Regulations (CCR) require any Outsourcing Facility licensed in the state of California to be compliant with federal current Good Manufacturing Practices (cGMP) and other federal laws as specified in Section 1750. **The assessment shall be performed before July 1 of every odd-numbered year by the facility’s designated quality control person (as defined in CCR section 1750.1).** The designated quality control personnel must also complete a self-assessment within 30 days whenever: (1) a new outsourcing license has been issued; (2) there is a change in the designated quality control personnel; or (3) there is a change in the licensed physical location of the outsourcing facility. The primary purpose of the self-assessment is to promote compliance through self-examination and education.

This self-assessment should be completed in its entirety, may be completed online, printed, initialed, signed and readily retrievable and available for Board inspection in the pharmacy as required by BPC section 4081. Do not copy a previous assessment. This is meant as a guide for Board requirements for filling a patient specific prescription to be furnished within and into the state of California by a licensed Outsourcing Facility.

**Note:** The licensed Outsourcing Facility can only dispense compounded drug preparations from its licensed location pursuant to a prescription within or into the state of California. Further, Outsourcing Facilities are not licensed pharmacies and may not provide or accept transferred prescriptions from pharmacies or other outsourcing facilities.

All references to the Business and Professions Code (BPC) are to Division 2, Chapter 9. All references to the California Code of Regulations (CCR) are to Title 16.

**Each self-assessment must be kept on file in the facility for three years after it is performed.**

Facility Name: \_\_\_\_\_

Address: \_\_\_\_\_ Phone: \_\_\_\_\_

Ownership: Sole Owner  Partnership  Corporation  LLC  Trust   
 Other  (please specify) \_\_\_\_\_

License #: \_\_\_\_\_ Exp. Date: \_\_\_\_\_ Date of Last FDA Inspection: \_\_\_\_\_

FDA EIN #: \_\_\_\_\_ Registration Date: \_\_\_\_\_ DEA Number: \_\_\_\_\_

Name(s) of Designated Quality Control Personnel Responsible for Compliance (attach additional sheets if necessary): \_\_\_\_\_

Hours: Weekdays \_\_\_\_\_ Sat \_\_\_\_\_ Sun. \_\_\_\_\_ 24 Hours \_\_\_\_\_

Website address (optional): \_\_\_\_\_

\_\_\_\_\_  
 Initials

**Facility Staff (Please include license type and license number where appropriate):** (Please use additional sheets if necessary)

1. \_\_\_\_\_

2. \_\_\_\_\_

3. \_\_\_\_\_

4. \_\_\_\_\_

5. \_\_\_\_\_

6. \_\_\_\_\_

7. \_\_\_\_\_

8. \_\_\_\_\_

9. \_\_\_\_\_

10. \_\_\_\_\_

11. \_\_\_\_\_

12. \_\_\_\_\_

13. \_\_\_\_\_

14. \_\_\_\_\_

15. \_\_\_\_\_

16. \_\_\_\_\_

17. \_\_\_\_\_

18. \_\_\_\_\_

19. \_\_\_\_\_

20. \_\_\_\_\_

TO BE ADOPTED

Please mark the appropriate box for each question. If "NO", enter an explanation on "CORRECTIVE ACTION OR ACTION PLAN" lines at the end of the section. If more space is needed, you may add additional sheets.

**Section I**  
**Prescription Specific Regulations**

**Duties of a pharmacist in an Outsourcing Facility filling patient specific prescriptions**

**1. A pharmacist:**

Yes No N/A

- 1.1 Transmits a valid prescription to another pharmacist; (BPC 4052[a][2])
- 1.2 Provides consultation, training, and education to patients about drug therapy disease management and disease prevention; (BPC 4052[a][8])
- 1.3 Receives a new prescription order from the prescriber; (BPC 4070[a]), (CCR 1793.1[a])
- 1.4 Consults with the patient; (BPC 4052[a][8], CCR 1707.2, CCR 1793.1[b])
- 1.5 Identifies, evaluates, and interprets a prescription; (CCR 1793.1[c])
- 1.6 Interprets the clinical data in a patient medication record; (CCR 1793.1[d])
- 1.7 Consults with any prescriber, nurse, health professional or agent thereof; (1793.1[e])

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

\_\_\_\_\_

**2. Patient Consultation**

Yes No N/A

- 2.1 Pharmacists provide oral consultation: (BPC 4052[a][8], CCR 1707.2)
  - 2.1.1 Whenever the prescription drug has not been previously dispensed to the patient;
  - 2.1.2 Whenever a refill prescription drug is dispensed in a different dosage form, strength, or with new written directions;
  - 2.1.3 Upon request;
  - 2.1.4 Whenever the pharmacist deems it is warranted in the exercise of his or her professional judgment; and
  - 2.1.5 All the above, unless a patient or patient's agent declines the consultation directly to the pharmacist.
- 2.2 The facility maintains patient profile information including allergies, date of birth or age, gender and other prescription and nonprescription drugs that the patient takes. (CCR 1707.1)
- 2.3 The pharmacist reviews a patient's drug therapy and medication record prior to consultation. (CCR 1707.3)
- 2.4 Consultation is performed in a manner that protects the patient's protected health care information and in an area suitable for confidential patient consultation and provided in accordance with nondisclosure obligations of Civil Code 56.10. (Civil Code 56.10, CCR 1714[a], 1764)

Yes No N/A

\_\_\_\_\_  
Initials

- 2.5 Appropriate drug warnings are provided orally or in writing. (BPC 4074, CCR 1744)
- 2.6 If prescription medication is mailed or delivered, the facility ensures that: (CCR 1707.2[b][1])
  - 2.6.1 The patient receives written notice of his or her right to request consultation (CCR 1707.2 [b][1][A]);
  - 2.6.2 The patient receives written notice of the hours of availability and the telephone number from which the patient may obtain oral consultation (CCR 1707.2 [b][1][B]);
  - 2.6.3 A pharmacist is available to speak with the patient or patient's agent during any regular hours of operation, within an average of ten (10) minutes or less, unless a return call is schedule to occur within one business hour, for no fewer than six days per week, and for a minimum of 40 hours per week (CCR 1707.2 [b][1][C]).

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

---

### 3. Prescription Requirements

Yes No N/A

- 3.1 Prescriptions or electronic data transmission prescriptions are complete with all the required information and, if electronic, reduced to the required writing by a pharmacist. (BPC 4040, 4070)
- 3.2 Orally transmitted prescriptions are received and reduced to writing only by a Pharmacist. (BPC 4070[a], CCR 1717[c])
- 3.3 If a prescription is orally or electronically transmitted by the prescriber's agent, the pharmacist makes a reasonable attempt to verify that the prescriber's agent is authorized to do so, and the agent's name is recorded. (BPC 4071)
- 3.4 If orally transmitted, the pharmacist who received the prescription is identified by initialing the prescription, and if dispensed by another pharmacist, the dispensing pharmacist also initials the prescription. (CCR 1717[c], 1712)
- 3.5 The security, accuracy and confidentiality of electronically transmitted prescriptions are maintained. (BPC 4070[c], CCR 1717.4[h])
- 3.6 Facsimile prescriptions are received from a prescriber's office. (BPC 4040[c])
- 3.7 Internet prescriptions for patients (human or animal) in this state are only dispensed or furnished pursuant to a prior good faith examination. (BPC 4067[a])
- 3.8 Except for those prescriptions written under Health and Safety Code (HSC) sections 11159.2, 11159.3 and 11167.5, all written controlled substances prescriptions (Schedules II - V) are on California Security Prescription forms meeting the requirements of HSC 11162.1. (HSC 11162.1, 11164[a], 11167.5)
- 3.9 All controlled substance prescriptions are valid for six months and are signed and dated by the prescriber. (HSC 11164[a][1], 11166)
- 3.10 All controlled substance prescriptions that are e-prescribed conform to provisions of federal law. (21 CFR 1306.08, 1306.11, 1311.100)
- 3.11 The facility confirms compliance with the following: "No person shall dispense a controlled substance pursuant to a preprinted multiple check-off prescription blank. A person may dispense a dangerous drug that is not a controlled substance pursuant to a preprinted multiple checkoff prescription blank and may dispense more than one dangerous drug, that is not a controlled substance,

\_\_\_\_\_  
Initials

pursuant to such a blank if the prescriber has indicated on the blank the number of dangerous drugs they have prescribed. 'Preprinted multiple checkoff prescription blank,' as used in this section means any form listing more than one dangerous drug where the intent is that a mark next to the name of a drug, i.e., a 'checkoff,' indicates a prescription order for that drug." (CCR 1717.3)

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

---

#### 4. Refill Authorization

Yes No N/A

- 4.1 Refill authorization from the prescriber for dangerous drugs or dangerous devices is obtained before refilling a prescription. (BPC 4063, 4064[a])
- 4.2 Prescriptions for dangerous drugs or devices are only filled without the prescriber's authorization if the prescriber is unavailable to authorize the refill and if, in the pharmacist's professional judgment, failure to refill the prescription might interrupt the patient's ongoing care and have a significant adverse effect on the patient's well-being. (BPC 4064)
- 4.3 Refills are documented. (CCR 1717)
- 4.4 Refills for Schedule II controlled substances are prohibited. (HSC 11200[c])
- 4.5 Refills for Schedule III and IV controlled substance prescriptions are limited to a maximum of 5 times within 6 months, and all refills taken together do not exceed a 120-day supply. (HSC 11200[a]-[b])

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

---

#### 5. Medication Errors related to a patient specific prescription

Yes No N/A

- 5.1 The facility has an established quality assurance program that documents medication errors attributable, in whole or in part, to the facility or its personnel. (BPC 4125, CCR 1711)
- 5.2 Quality assurance policies and procedures are maintained in the facility and are immediately retrievable. (CCR 1711[c])
- 5.3 The pharmacist communicates with the patient or patient's agent that a medication error has occurred, and the steps required to avoid injury or mitigate the error. (CCR 1711[c][2][A], 1711[c][3])
- 5.4 When a medication error has occurred (drug was administered to or by the patient or resulted in a clinically significant delay in therapy) the pharmacist communicates to the prescriber that a medication error has occurred. (CCR 1711[c][2][B], 1711[c][3])
- 5.5 Investigation of the medication errors is initiated within two business days from the date the medication error is discovered. (CCR 1711[d])

Yes No N/A

- 5.6 In addition to all complaint and adverse drug reaction tracking compliant with the

\_\_\_\_\_  
Initials

CFR, the record for quality assurance review for a medication error contains:  
(CCR 1711[e])

- 5.6.1 Date, location, and participants in the quality assurance review;
- 5.6.2 Pertinent data and other information related to the medication error(s) reviewed;
- 5.6.3 Findings and determinations; and
- 5.6.4 Recommended changes to policy, procedure, systems, or processes, if any.

- 5.7 The record of the quality assurance review is immediately retrievable in the facility and is maintained in the facility for at least one year from the date it was created. (CCR 1711[f])

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

---

## 6. Erroneous or Uncertain prescriptions

Yes No N/A

- 6.1 If a prescription contains any significant error, omission, irregularity, uncertainty, ambiguity or alteration, the pharmacist contacts the prescriber to obtain information needed to validate the prescription. (CCR 1761[a])
- 6.2 Pharmacists are aware of their corresponding responsibility to determine that a prescription written for a controlled substance was issued for legitimate medical purposes only. (HSC 11153)
- 6.3 Even after conferring with the prescriber, the pharmacist does not dispense a controlled substance prescription if they know or have objective reason to know that the prescription was not issued for a legitimate medical purpose. (CCR 1761[b], HSC 11153)
- 6.4 Internet prescriptions for controlled substances are only dispensed if in compliance with the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. (21 USC 802, 829[e])

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

---

## 7. Labeling for a patient specific prescription

Yes No N/A

- 7.1 In addition to the requirements for labeling listed in the CFR, the prescription label contains all the required information specified in BPC 4076. (BPC 4076)
- 7.2 The prescription label is formatted in accordance with patient centered labeling requirements. (CCR 1707.5)
- 7.3 The beyond use date of a drug's effectiveness is accurately identified on the label. (BPC 4076[a][9])
- 7.4 The trade name or generic name and manufacturer of the prescription drug is accurately identified on the label and prescription record and includes the statement "generic for \_\_\_ " where the brand name is inserted, and the name of the

\_\_\_\_\_  
Initials

manufacturer. In the professional judgment of the pharmacist, if the brand name is no longer widely used, the label may list only the generic name of the drug and the manufacturer's name may be listed outside the patient-centered area. (BPC 4076[a][1], CCR 1707.5[a][1][B], CCR 1717[b][2])

- 7.5 The federal warning label prohibiting transfer of controlled substances is on the prescription container. (21 CFR 290.5)
- 7.6 The label includes a physical description of the dispensed medication, including its color, shape, and any identification code that appears on the tablets or capsules. (BPC 4076[a][11])
- 7.7 Whenever an opioid prescription drug is dispensed to patient for outpatient use, the facility prominently displays on the label or container or by a flag or other notification to the container, a notice that states, "Caution: Opioid. Risk of overdose and addiction." (BPC 4076.7)
- 7.8 When requested by a patient or patient representative, the facility provides translated directions for use, printed on the prescription container, label, or on a supplemental document. If the translated directions for use appear on the prescription container or label, the English-language version of the directions for use also appears on the container or label, whenever possible, and may appear on other areas of the label outside the patient-centered area. If it is not possible for the English-language directions to appear on the container or label, the English-language directions are provided on a supplemental document. (BPC 4076.6[a])
- 7.9 The pharmacist includes a written label on the drug container indicating that the drug may impair a person's ability to operate a vehicle or vessel. The label may be printed on an auxiliary label affixed to the prescription container. (BPC 4074[b], BPC 4076.7, CCR 1744[a])
- 7.10 The pharmacist includes a written label on the drug container to alert the patient about possible potentiating effects when taken in combination with alcohol. The label may be printed on an auxiliary label affixed to the prescription container. (CCR 1744[b])

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_  
\_\_\_\_\_

## 8. Furnishing and Dispensing

Yes No N/A

- 8.1 If the prescription is filled by a pharmacy technician, before dispensing, the prescription is checked for accuracy by a licensed pharmacist and that pharmacist initials the prescription label or records by their identity as the reviewing pharmacist in a computer system by a secure means. (BPC 4115, 4115.5[b][3], CCR 1712, 1793.7[a])

Yes No N/A

- 8.2 Prescriptions are dispensed in a new and child-resistant container, or senior-adult ease-of-opening tested container, or in a non-complying package only pursuant to the prescriber or when requested by the purchaser. (15 USC 1473[b], 16 CFR 1700.15, CCR 1717[a])
- 8.3 Patient package inserts are dispensed with all estrogen medications.

\_\_\_\_\_  
Initials

(21 CFR 310.515)

- 8.4 The facility provides patients with Black Box Warning Information in conformance with 21 CFR 201.57[c]. (21 CFR 201.57[c])
- 8.5 Medication guides are provided on required medications. (21 CFR, Part 208)
- 8.6 The facility furnishes dangerous drugs in compliance with BPC 4126.5 only to a patient pursuant to a prescription. (BPC 4126.5[a][5])
- 8.7 Controlled substance prescriptions are not filled or refilled more than six months from the date written. (HSC 11200[a])
- 8.8 Refills for Schedule III and IV controlled substance prescriptions are limited to a maximum of 5 times and in an amount, for all refills of that prescription taken together, not exceeding a 120-day supply. (HSC 11200[b])
- 8.9 The facility dispenses not more than a 90-day supply of a dangerous drug, excluding controlled substances, under the following provisions: (BPC 4064.5).
  - 8.9.1 The prescription specifies an initial quantity of less than a 90-day supply followed by periodic refills; (BPC 4064.5[a])
  - 8.9.2 The prescriber has not indicated "no change to quantity" or words of similar meaning; (BPC 4064.5[d])
  - 8.9.3 The patient has completed an initial 30-day supply (this is not required where the prescription continues the same medication as previously dispensed in a 90-day supply); (BPC 4064.5[a][1], 4064.5[b])
  - 8.9.4 The total quantity dispensed does not exceed the total quantity authorized on the prescription, including refills; (BPC 4064.5[a][2])
  - 8.9.5 The prescriber has not specified on the prescription that dispensing the prescription in an initial amount, followed by periodic refills, is medically necessary; (BPC 4064.5[a][3])
  - 8.9.6 The pharmacist is exercising their professional judgment; and (BPC 4064.5[a][4])
  - 8.9.7 The pharmacist notifies the prescriber of the increase in quantity dispensed. (BPC 4064.5[c])

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

\_\_\_\_\_

## 9. Confidentiality of Prescriptions

Yes No N/A

- 9.1 Patient information is maintained to safeguard confidentiality. (Civil Code 56 et seq.)
- 9.2 All prescriptions are kept confidential and only disclosed as authorized by law. (CCR 1764)
- 9.3 The facility ensures electronically transmitted prescriptions are received maintained and transmitted in a secure and confidential manner. (CCR 1717.4[h])

Yes No N/A

- 9.4 If electronically transmitted prescriptions are received by an interim storage device (to allow for retrieval at a later time), the facility maintains the interim storage device in a manner to prevent unauthorized access. (CCR 1717.4[d])
- 9.5 If the facility has established and utilizes common electronic prescription files to maintain required dispensing information, the system shall not permit disclosure

\_\_\_\_\_  
Initials

of confidential medical information except as authorized by law. (CCR 1717.1)

- 9.6 Destruction or disposal of patient records preserves the confidentiality of the information contained therein. (Civil Code 56.101)

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**10. Record Keeping Requirements in addition to compliance with cGMP**

Yes No N/A

- 10.1 Completed self-assessments are kept on file in the facility and maintained for three years after completion. (CCR 1750.1[e])
- 10.2 All drug acquisition and disposition records (complete accountability) are maintained for at least three years. For any record maintained electronically, a hardcopy is able to be produced upon inspection and electronic copy of all records of acquisition or disposition or other drug or dispensing-related records, including: (BPC 4081, 4105, 4169, 4333, CCR 1718)
  - 10.2.1 Prescription records (BPC 4081[a])
  - 10.2.2 Purchase Invoices for all prescription drugs (BPC 4081[b])
  - 10.2.3 Purchase Invoices and sales records for non-prescription diabetic test devices dispensed pursuant to a prescription (BPC 4081[d])
  - 10.2.4 Biennial controlled substances inventory (21 CFR 1304.11)
  - 10.2.5 U.S. Official Order Forms (DEA Form 222) (21 CFR 1305.13)
  - 10.2.6 Power of Attorney for completion of DEA 222 forms (21 CFR 1305.05)
  - 10.2.7 Theft and Loss Reports (DEA Form 106) (21 CFR 1301.74[c])

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**11. Patient specific prescriptions may not be returned and reused by the facility.**

Yes No N/A

- 11.1 Patient specific prescriptions are not returned and reused by the facility.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

\_\_\_\_\_  
Initials

**Section II**  
**Code of Federal Regulation Part 211 for all Outsourcing Facilities**

**Quality Systems, validation control, facility control and training**

**12. CFR Part 211, Subpart B, Organization and Personnel**

Yes No N/A

12.1 Compliance with sections 211.22 through 211.34 in their entirety

**Facility**

**13. CFR Part 211, Subpart C Buildings and Facilities**

Yes No N/A

13.1 Compliance with Sections 211.42 through 211.58 in their entirety.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**Equipment**

**14. CFR Part 211, Subpart D Equipment**

Yes No N/A

14.1 Compliance with sections 211.63 through 211.72 in their entirety.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**Compounding and manufacture of the product**

**15. CFR Part 211, Subpart E Control of Components and Drug Product Containers and Closures**

Yes No N/A

15.1 Compliance with sections 211.80 through 211.94 in their entirety.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**16. CFR Part 211, Subpart F—Production and Process Controls**

Yes No N/A

11.1 Compliance with sections 211.100 through 211.115 in their entirety.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

\_\_\_\_\_  
Initials

**17. CFR Part 211, Subpart G—Packaging and Labeling Control**

Yes No N/A

17.1 Compliance with sections 211.122 through 211.137 in their entirety.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**Distribution, storage,**

**18. CFR Section 211, Subpart H—Holding and Distribution**

Yes No N/A

19.1 Compliance with sections 211.142 through 211.150

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**Release of product for sale**

**19. CFR Section 211, Subpart I—Laboratory Controls**

Yes No N/A

18.1 Compliance with sections 211.160 through 211.176 in their entirety.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**Record keeping**

**20. CFR Part 211, Subpart J—Records and Reports**

Yes No N/A

20.1 Compliance with sections 211.180 through 211.198 in their entirety.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**Returns**

**21. CFR part 211, Subpart K—Returned and Salvaged Drug Products**

Yes No N/A

21.1 Compliance with sections 211.204 through 211.208 in their entirety for products not sold pursuant to a patient specific prescription.

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

\_\_\_\_\_  
Initials

**Section III**  
**DEA Controlled Substances Inventory, as applicable to your facility**

**22. Inventory:**

Yes No N/A

- 22.1 Is completed biennially (every two years). (21 CFR 1304.11[c])
- 22.2 Schedule II inventory is separate from Schedule III, IV and V. (21 CFR 1304.04[h][1])
- 22.3 All completed inventories are available for inspection for three years. (CCR 1718)
- 22.4 Indicates on the inventory record whether the inventory was taken at the open of business or at the close of business. (21 CFR 1304.11 [a])
- 22.5 Separate Schedule II records are maintained. This includes Schedule II prescriptions, invoices, US official order forms, and inventory records. (21 CFR 1304.04[h])
- 22.6 Schedule III-V prescriptions are filed separately from all prescription records or are designated with a red "C." However, the red C requirement is waived if the facility uses an automated data processing or other record keeping system for identification of controlled substances by prescription number and the original prescription documents can be retrieved promptly. (21 CFR 1304.04[h][4])
- 22.6 Inventories and records for Schedule III-V controlled substances are filed separately or are designated in some manner that makes the required information readily retrievable from ordinary business records. (21 CFR 1304.04)
- 22.7 A U.S. Official Order Form (DEA Form 222) or electronic equivalent (CSOS) is utilized when ordering all Schedule II-controlled substances. When Schedule II Controlled substance orders are received by the facility, for each item received, the date and quantity received is indicated on the DEA Form 222. (21 CFR 1305.03, 1305.12, 1305.13, 1305.21, 1305.22[g])
- 22.8 When dispensed upon an "oral" order for a true emergency, a Schedule II prescription is provided by the prescriber by the 7th day following the transmission of the oral order. If not received, the facility reports failure to provide prescription document to the California Bureau of Narcotic Enforcement within 144 hours of the failure to provide the prescription. (HSC 11167[c]-[d])
- 22.9 The facility generates a controlled substances printout for refills of Schedule II-V prescriptions at least every three days (72 hours) which contains the signature of the dispensing pharmacist, or the facility maintains an alternate system to document the refilling of controlled substance prescriptions that complies with 21 CFR 1306.22.
- 22.10 Any controlled substances drug theft or significant loss is reported within one business day of discovery to the DEA (21 CFR 1301.74[c].)
- 22.11 A report is submitted to the Board within 30 days of the date of discovery of any loss of a controlled substance or any other significant drug losses as specified in Section 1715.6. (CCR 1715.6)
- 22.12 Pharmacists are creating initial prescription records and prescription labels by hand, or a pharmacist initials or signs prescription records and prescription labels by recording the identity of the pharmacist in a computer system by a secure means. This computer system does not permit the record to be altered after made and the record of the pharmacist's identity made in the computer system is immediately retrievable in the facility. (CCR 1712, 1717[b][1], 1717[f])

Yes No N/A

\_\_\_\_\_  
Initials

- 22.13 All Schedule II through V controlled substances dispensing data is successfully transmitted within one working day from the date the controlled substance is released to the patient through the CURES System Administrator. [HSC 11165(d)]
- 22.14 The facility has designed and operates a system to identify suspicious orders and ensures the system complies with applicable Federal and State privacy laws. Upon discovering a suspicious order or series of orders, notify the DEA administration and the Special Agent in charge of DEA in their area. (21 USC 832[a])

CORRECTIVE ACTION OR ACTION PLAN: \_\_\_\_\_

**DESIGNATED QUALITY CONTROL PERSONNEL CERTIFICATION:**

I, (please print) \_\_\_\_\_, Title \_\_\_\_\_ hereby certify that I have completed the self-assessment of this outsourcing facility of which I am the designated quality control person. Any deficiency identified herein will be corrected by \_\_\_\_\_ (date). I understand that all responses are subject to verification by the Board of Pharmacy. I further state under penalty of perjury of the laws of the State of California that the information that I have provided in this self-assessment form is true and correct.

Signature \_\_\_\_\_ Date \_\_\_\_\_  
 (Designated Quality Control Personnel)

**ACKNOWLEDGEMENT BY FACILITY OWNER OR OFFICER:**

I, (please print) \_\_\_\_\_, hereby certify under penalty of perjury of the laws of the State of California that I have read and reviewed this completed self-assessment. I understand that failure to correct any deficiency identified in this self-assessment in the timeframe identified in the Designated Quality Control Personnel Certification above could result in the revocation of the outsourcing facility's license issued by the California State Board of Pharmacy.

Signature \_\_\_\_\_ Date \_\_\_\_\_  
 (Outsourcing Facility Owner or Officer)

\_\_\_\_\_  
 Initials

The following **Legal References** are used in the self-assessment form. Many of these references can be viewed on the Board of Pharmacy Web site at [www.pharmacy.ca.gov](http://www.pharmacy.ca.gov) (see *Laws and Regulations*), at the California State Law Library, or at other libraries or Internet web sites.

- Business and Professions Code, Division 1, Chapter 1 – General Provisions
- Business and Professions Code, Division 2, Chapter 1 – General Provisions
- Business and Professions Code, Division 2, Chapter 9 – Pharmacy
- California Code of Regulation, Title 16, Division 17 – California State Board of Pharmacy
- Civil Code, Division 1, Part 2.6, Chapter 2 – Disclosure of Medical Information by Providers
- Code of Federal Regulations, Title 16, Chapter II, Subchapter E, Part 1700 – Poison Prevention Packaging
- Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 210 – Current Good Manufacturing Practice in Manufacturing, Processing, Packaging, or Holding of Drugs; General
- Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals
- Code of Federal Regulations, Title 21, Chapter II, Parts 1301, 1304, 1305, 1306, 1311
- Health and Safety Code, Division 10 – Uniform Controlled Substances Act
- Health and Safety Code, Division 104, Part 5 - Sherman Food, Drug, and Cosmetics Law
- United States Code, Title 21, Chapter 9, Subchapter V, Part A – Federal Food, Drug, and Cosmetic Act
- United States Code, Title 21, Chapter 13 – Drug Abuse Prevention and Control